Page 460 - Essential Haematology

446 / Index

myelodysplasia (continued) myoglobin 35 recurrent infections 120
laboratory fi ndings 217, 218, 219 myxoedema 388 refractory 215
pathogenesis 216 neutrophil(s) 109, 110, 111
platelet function abnormalities N bone marrow 111–12
342 NADH 22, 23, 24 function disorders 114–17
primary 216 natural killer (NK) cell(s) 129–30 killing and digestion 114–15
progression to AML 215 natural killer (NK) cell neoplasms, kinetics 111
risk groups 216, 219, 221 mature 428–9 leucocytosis 116, 117
secondary 216 necrosis 12–13 morphology abnormalities 116,
sideroblastic anaemia 47 Neisseria meningitidis, risk in 117
therapy-related 216 hyposplenism 148 precursors 110–11
myelodysplastic/myeloproliferative neonatal jaundice 80 neutrophil alkaline phosphatase
neoplasms 221–2, 427 neonates 416, 417, 418–19, (NAP) score 388
myelodysplastic syndrome 420–1, 422 NF1 gene mutation 222
associated with isolated del(5q) anaemia 416, 417, 418 nicotinamide adenine dinucleotide
215, 216 anaemia of prematurity 418 phosphate (NADPH) 22,
childhood 215 blood count 416 24, 115
WHO classifi cation 427 coagulation 418 Niemann–Pick disease 125
myelofi brosis, primary 203, fetomaternal alloimmune nilotinib 196, 198, 199
210–11 thrombocytopenia 418 nitric oxide 320, 321
clinical features 210–11 haemorrhagic disease of the endothelial cells 324
laboratory fi ndings 211 newborn 354–5 nitrous oxide (N 20) anaesthesia 71
treatment 211 intracranial haemorrhage 416 non-Hodgkin lymphoma 151, 246,
myeloid growth factors 112 mothers with idiopathic 254–71
myeloid proliferations related to thrombocytopenic B-cell 254, 255, 256
Down’s syndrome 181 purpura 416 cell of origin 255, 256
myeloid sarcoma 179, 181 polycythaemia 418 classifi cation 254–5
myeloma see also haemolytic disease of the clinical features 256–7
asymptomatic 274 newborn cytogenetics 258, 259, 260, 262
autologous stem cell nephrotic syndrome 387 donor leucocyte infusions 311
transplantation 303 neural tube defects high-grade 255–6, 267–9
see also multiple myeloma folate/vitamin B 12 defi ciency 66, HIV infection 391
myeloma cell 273 67 investigations 257–8
myeloperoxidase defi ciency 116 folic acid prophylaxis 71, 414 laboratory investigations 257–8
myeloproliferative disorders neurofi bromatosis 222 low-grade 255–6, 261–2, 265–7
genetic abnormalities 155, 157 neutropenia 118–21 lymph node biopsy 257, 258
JAK2 mutation 203, 204, 205 ALL 224 lymphocytosis 242
non-leukaemic neoplasms autoimmune 119, 120 peripheral T-cell, unspecifi ed
203–13 benign ethnic 119 269
platelet function abnormalities clinical features 119, 120 staging 260–1, 263, 264
342 congenital 119 subtypes 261–2, 265–9
venous thrombosis 369 cyclical 119 T-cell 254, 255
see also polycythaemia; diagnosis 119 white cell changes 382
polycythaemia vera drug-induced 119, 120 Noonan’s syndrome 222
myeloproliferative neoplasms 427 haematological malignancies normocytic, normochromic anaemia
myelosuppression, cytotoxic in 169–70 27
polycythaemia vera idiopathic benign 119 NOTCH signalling pathway, T-cell
206–7 management 120 ALL 228, 229